{"id":3675,"date":"2016-03-14T17:17:03","date_gmt":"2016-03-14T15:17:03","guid":{"rendered":"http:\/\/backup.altanalaw.com\/?p=3675"},"modified":"2016-03-14T17:19:35","modified_gmt":"2016-03-14T15:19:35","slug":"altana-conseille-onxeo-dans-lacquisition-de-dna-therapeutics","status":"publish","type":"post","link":"https:\/\/backup.altanalaw.com\/en\/medias\/altana-conseille-onxeo-dans-lacquisition-de-dna-therapeutics","title":{"rendered":"Altana advises ONXEO in the acquisition of DNA Therapeutics"},"content":{"rendered":"

Altana advises ONXEO, a company listed on Compartment B of Euronext Paris and on the Copenhagen NASDAQ, in the execution of a binding agreement to acquire DNA Therapeutics. <\/strong><\/p>\n

DNA Therapeutics is a biopharmaceutical company, with first-in-class therapeutic molecule in the cancer treatment. This new acquisition allows ONXEO to expand its pipeline and opens new opportunities in new orphan oncology indications.<\/p>\n

The acquisition of DNA Therapeutics demonstrates once again ONXEO\u2019s commitment to be a leader in the development of new drugs in the orphan oncology treatments and ranks the Company at the forefront of scientific research with the potential to generate significant value for its stakeholders.<\/p>\n

According to the terms of the agreement; ONXEO will acquire DNA Therapeutics for an upfront payment of \u20ac\u00a01.7 million payable at closing in ONXEO common shares. An additional payment will be made in an amount of \u20ac 1 million payable in ONXEO shares or in cash at ONXEO\u2019s discretion, upon successful initiation of a Phase II trial in one of the selected indications. Finally, royalty payments on future commercial sales will be payable up to \u20ac\u00a025 million per indication.<\/p>\n

ALTANA had previously advised ONXEO (formerly BIOALLIANCE PHARMA) in its cross-border merger with the Danish company TOPOTARGET in 2014. This merger was the first-ever cross border merger of a French listed company with a listed company of a different nationality under the 2005 merger Directive.<\/p>\n

– Acquirer: ONXEO<\/strong><\/span><\/p>\n

– Legal advisors: ALTANA (Jean-Nicolas Soret \/ Fabien Pouchot)<\/p>\n

– Tax advisors: ARSENE TAXAND (Olivier Vergniolle \/ Marion Dervieux)<\/p>\n

– Financial advisors: ERNST & YOUNG (J\u00e9r\u00f4me Vailland \/ Mehdi Houkari)<\/p>\n

– Seller: DNA Therapeutics Shareholders<\/span><\/strong><\/p>\n

– Legal advisors: HBC Avocats (Erwan Coss\u00e9 \/ Laurent Comperot)<\/p>","protected":false},"excerpt":{"rendered":"

Altana advises ONXEO, a company listed on Compartment B of Euronext Paris and on the Copenhagen NASDAQ, in the execution of a binding agreement to acquire DNA Therapeutics.<\/p>\n","protected":false},"author":14,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-3675","post","type-post","status-publish","format-standard","hentry","category-medias","expertise-droit-societes-fusions-acquisitions"],"yoast_head":"\nAltana advises ONXEO in the acquisition of DNA Therapeutics - Advant Altana<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"[:fr]Altana conseille ONXEO dans l'acquisition de DNA Therapeutics[:en]Altana advises ONXEO in the acquisition of DNA Therapeutics[:] - Advant Altana\" \/>\n<meta property=\"og:description\" content=\"[:fr]ALTANA conseille ONXEO, soci\u00e9t\u00e9 cot\u00e9e sur le compartiment B d\u2019Euronext Paris et sur le NASDAQ Copenhague, dans le cadre de la conclusion d\u2019un accord engageant relatif \u00e0 l\u2019acquisition de DNA Therapeutics.[:en]Altana advises ONXEO, a company listed on Compartment B of Euronext Paris and on the Copenhagen NASDAQ, in the execution of a binding agreement to acquire DNA Therapeutics. [:]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/backup.altanalaw.com\/medias\/altana-conseille-onxeo-dans-lacquisition-de-dna-therapeutics\" \/>\n<meta property=\"og:site_name\" content=\"Advant Altana\" \/>\n<meta property=\"article:published_time\" content=\"2016-03-14T15:17:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2016-03-14T15:19:35+00:00\" \/>\n<meta name=\"author\" content=\"Altana Communication\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Altana Communication\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/backup.altanalaw.com\/medias\/altana-conseille-onxeo-dans-lacquisition-de-dna-therapeutics\",\"url\":\"https:\/\/backup.altanalaw.com\/medias\/altana-conseille-onxeo-dans-lacquisition-de-dna-therapeutics\",\"name\":\"[:fr]Altana conseille ONXEO dans l'acquisition de DNA Therapeutics[:en]Altana advises ONXEO in the acquisition of DNA Therapeutics[:] - Advant Altana\",\"isPartOf\":{\"@id\":\"https:\/\/backup.altanalaw.com\/#website\"},\"datePublished\":\"2016-03-14T15:17:03+00:00\",\"dateModified\":\"2016-03-14T15:19:35+00:00\",\"author\":{\"@id\":\"https:\/\/backup.altanalaw.com\/#\/schema\/person\/4bdb47072f79b38f30b44735a4377af6\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/backup.altanalaw.com\/medias\/altana-conseille-onxeo-dans-lacquisition-de-dna-therapeutics\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/backup.altanalaw.com\/#website\",\"url\":\"https:\/\/backup.altanalaw.com\/\",\"name\":\"Advant Altana\",\"description\":\"Soci\u00e9t\u00e9 d'avocats \u00e0 la Cour de Paris\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/backup.altanalaw.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/backup.altanalaw.com\/#\/schema\/person\/4bdb47072f79b38f30b44735a4377af6\",\"name\":\"Altana Communication\",\"url\":\"https:\/\/backup.altanalaw.com\/en\/author\/altanacomm\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"[:fr]Altana conseille ONXEO dans l'acquisition de DNA Therapeutics[:en]Altana advises ONXEO in the acquisition of DNA Therapeutics[:] - Advant Altana","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"[:fr]Altana conseille ONXEO dans l'acquisition de DNA Therapeutics[:en]Altana advises ONXEO in the acquisition of DNA Therapeutics[:] - Advant Altana","og_description":"[:fr]ALTANA conseille ONXEO, soci\u00e9t\u00e9 cot\u00e9e sur le compartiment B d\u2019Euronext Paris et sur le NASDAQ Copenhague, dans le cadre de la conclusion d\u2019un accord engageant relatif \u00e0 l\u2019acquisition de DNA Therapeutics.[:en]Altana advises ONXEO, a company listed on Compartment B of Euronext Paris and on the Copenhagen NASDAQ, in the execution of a binding agreement to acquire DNA Therapeutics. [:]","og_url":"https:\/\/backup.altanalaw.com\/medias\/altana-conseille-onxeo-dans-lacquisition-de-dna-therapeutics","og_site_name":"Advant Altana","article_published_time":"2016-03-14T15:17:03+00:00","article_modified_time":"2016-03-14T15:19:35+00:00","author":"Altana Communication","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Altana Communication","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/backup.altanalaw.com\/medias\/altana-conseille-onxeo-dans-lacquisition-de-dna-therapeutics","url":"https:\/\/backup.altanalaw.com\/medias\/altana-conseille-onxeo-dans-lacquisition-de-dna-therapeutics","name":"[:fr]Altana conseille ONXEO dans l'acquisition de DNA Therapeutics[:en]Altana advises ONXEO in the acquisition of DNA Therapeutics[:] - Advant Altana","isPartOf":{"@id":"https:\/\/backup.altanalaw.com\/#website"},"datePublished":"2016-03-14T15:17:03+00:00","dateModified":"2016-03-14T15:19:35+00:00","author":{"@id":"https:\/\/backup.altanalaw.com\/#\/schema\/person\/4bdb47072f79b38f30b44735a4377af6"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/backup.altanalaw.com\/medias\/altana-conseille-onxeo-dans-lacquisition-de-dna-therapeutics"]}]},{"@type":"WebSite","@id":"https:\/\/backup.altanalaw.com\/#website","url":"https:\/\/backup.altanalaw.com\/","name":"Advant Altana","description":"Soci\u00e9t\u00e9 d'avocats \u00e0 la Cour de Paris","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/backup.altanalaw.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/backup.altanalaw.com\/#\/schema\/person\/4bdb47072f79b38f30b44735a4377af6","name":"Altana Communication","url":"https:\/\/backup.altanalaw.com\/en\/author\/altanacomm"}]}},"_links":{"self":[{"href":"https:\/\/backup.altanalaw.com\/en\/wp-json\/wp\/v2\/posts\/3675"}],"collection":[{"href":"https:\/\/backup.altanalaw.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/backup.altanalaw.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/backup.altanalaw.com\/en\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/backup.altanalaw.com\/en\/wp-json\/wp\/v2\/comments?post=3675"}],"version-history":[{"count":2,"href":"https:\/\/backup.altanalaw.com\/en\/wp-json\/wp\/v2\/posts\/3675\/revisions"}],"predecessor-version":[{"id":3678,"href":"https:\/\/backup.altanalaw.com\/en\/wp-json\/wp\/v2\/posts\/3675\/revisions\/3678"}],"wp:attachment":[{"href":"https:\/\/backup.altanalaw.com\/en\/wp-json\/wp\/v2\/media?parent=3675"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/backup.altanalaw.com\/en\/wp-json\/wp\/v2\/categories?post=3675"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/backup.altanalaw.com\/en\/wp-json\/wp\/v2\/tags?post=3675"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}